Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Home

Marketplace
Database
News
Store
Resources
Contact Us

 

 

News


VENTURE CAPITAL DIRECTORY | PRIVATE EQUITY DIRECTORY

List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory

2021 NEW EDITION NOW AVAILABLE!
Buy Now for $119.95 with a free annual update in January 2022

Learn More or Buy Now

VCPro Database 2021 24th Edition -- a downloadable and searchable venture capital database with 6,500+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. (Updated JULY 2021)

Learn More » or Buy Now »




Entos Raises $53 Million Series A Round Led by Coatue and Catalio

Funding will Advance Entos’ Breakthrough AI and Quantum Mechanics-driven Drug Design Platform

Unique Integrated Platform Leveraging Proven Analytics and Proprietary Chemical Matter Enables Unprecedented Accuracy, Speed and Data Efficiency

Opens New San Diego Headquarters with State-of-the-Art Laboratory

SAN DIEGO, July 14, 2021-- Entos, Inc (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, today announced the closing of a $53 million Series A financing round led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.

The funding round was oversubscribed and represents a unique combination of sophisticated technology and life-sciences investors. As part of the fundraise, Aaron Weiner, Managing Director and Head of Healthcare at Coatue, and R. Jacob Vogelstein, Ph.D., Co-Founder and Managing Partner of Catalio, have joined Entos’ Board of Directors that includes Tom Miller, Co-Founder and Chief Executive Officer, Fred Manby, Co-Founder and Chief Technology Officer, and Naren Gupta, Co-Founder and Managing Director of Nexus Venture Partners.

Traditional therapeutic discovery is highly complex and entails prolonged timelines, vast training data needs and sub-optimal accuracy. Entos is eradicating these challenges with its cutting-edge OrbNet platform, an AI-driven drug and development process that creates a thousand-fold acceleration in molecular properties prediction with 100x less training data required. Through the OrbNet platform, Entos has already achieved meaningful customer traction with a growing portfolio of partnerships with industry leaders in pharmaceuticals, chemicals and materials.

“We are tremendously excited to have the opportunity, resources and team to revolutionize drug design with breakthrough AI technologies and chemical innovation,” said Tom Miller, Entos Co-Founder and Chief Executive Officer. “We look forward to partnering with some of the strongest investors in both tech and life-sciences, and welcome Aaron and Jacob to our world-class Board of Directors.”

“Drug development is a highly complex endeavor that is plagued by both cost and time inefficiency, and we believe that incorporating Entos’ impressive technology into the process will result in faster timelines and vastly improved therapeutics,” said Aaron Weiner, Managing Director and Head of Healthcare at Coatue. “Tom and Fred lead a team steeped in quantum mechanics and chemistry that is working to rethink the process of drug development. We are proud to partner with them and the rest of growing Entos team as they continue to achieve increased customer traction and seek their goal of revolutionizing the drug discovery process.”

Entos’ growing team is comprised of renowned scientists and engineers with world-class expertise in machine learning and software development, as well as computational and medicinal chemistry. Earlier this year, Entos further strengthened its leadership team with the appointment of Tim Cernak as Co-Founder and Chief Scientific Officer and Sarah Trice as Co-Founder and Chief Operating Officer. Dr. Cernak and Dr. Trice bring deep experience in drug development, high-throughput experimental, automated synthesis and medicinal chemistry software following extensive tenures at Merck. Entos is also supported by a star-studded Scientific Advisory Board that features prominent industry pioneers including Chemistry Nobel Prize winner Frances Arnold.

“There is a critical need for innovative drug design platforms that can rapidly deliver superior compounds to treat disease, and we can think of no group better suited than the Entos team to lead the industry into the future,” says Jacob Vogelstein, Co-Founder and Managing Partner of Catalio. “We believe that Entos’ unique combination of algorithms, software, and wetware can generate the highest quality drug candidates at unprecedented speed and scale.”

With the funds raised, Entos will meaningfully accelerate the development of its OrbNet AI-platform, including integrating the technology with robotic synthesis and high-throughput experimentation. The funds will also support an aggressive hiring agenda aimed to further strengthen Entos’ deep bench of science and engineering talent. The Company’s new headquarters in San Diego’s centrally located UCSD Science Park featuring state-of-the-art laboratory and office workspaces is designed to support Entos’ rapidly growing software, chemistry and biology teams.

About Entos

Founded in 2019 and headquartered in San Diego, California, Entos is focused on disrupting therapeutic discovery with OrbNet, its cutting-edge platform combining AI-driven technology and automated synthetic development to rapidly design small-molecule therapeutics. Driven by technology derived from Caltech and the University of Bristol, Entos’ team is comprised of renowned scientists and engineers – including Chemistry Nobel Prize winner Frances Arnold – with world-class expertise in machine learning and software development, as well as computational and medicinal chemistry. Learn more about Entos’ industry-revolutionizing platform at www.entos.ai.

Contact:
Media
David Millar/TJ White
Sard Verbinnen & Co.
Entos-SVC@sardverb.com


News Index

Venture Capital Database 

 

 NEWS

Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Business Plan Tools

Free Business Plan Template

 

Copyright © 1998-2021 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer